PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect
NanoViricides, Inc. reports positive results of broad-spectrum antiviral drug NV-387 in animal models, showing sustained antiviral effect with extended flat blood concentration profile upon oral administration -
-
-
PRESS RELEASE
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect
NanoViricides, Inc. reports positive pharmacokinetic profile of NV-387 in non-human primate model, showcasing sustained blood concentrations enabling less frequent dosing for its broad-spectrum antiviral agent. The unique polymeric design supports potential against RSV, COVID, and influenza -
-
-
PRESS RELEASE
A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More
NanoViricides, Inc. elaborates on its groundbreaking host-mimetic, broad-spectrum antiviral technology platform, NV-387, designed to revolutionize viral infection treatment with advanced decoy mechanisms
